Approval · Notice of Compliance 12223 · 2011
INTRON A: Notice of Compliance 12223
Issued March 24, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12223
- Date
- March 24, 2011
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Biological response modifier
Products in this notice
Medicinal ingredients
- INTERFERON ALFA 2B 15,000,000 UNIT per ML
- INTERFERON ALFA 2B 25,000,000 UNIT per ML
- INTERFERON ALFA 2B 50,000,000 UNIT per ML
- INTERFERON ALFA 2B 6,000,000 UNIT per ML
- INTERFERON ALFA 2B 10,000,000 UNIT per ML
- INTERFERON ALFA 2B 10,000,000 UNIT per VIAL
- INTERFERON ALFA 2B 18,000,000 UNIT per VIAL